Skip to main content

Table 5 Summary of efficacy by first-line treatment (TKI or chemotherapy) and TKI type (gefitinib or erlotinib) in the evaluable population

From: Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain

Endpoint First-line treatment TKI subtype
TKI CT CT + TKI maintenance Gefitinib Erlotinib
Evaluable 124 18 8 100 22
Response, n (%)
 CR 3 (2.2) 2 (11.1) 0 (0.0) 2 (2.0) 1 (4.5)
 PR 55 (44.4) 2 (11.1) 2 (25.9) 48 (48.0) 7 (31.8)
 SD 51 (41.1) 10 (55.6) 6 (75.0) 36 (36.0) 13 (59.1)
 PD 15 (12.1) 4 (22.2) 0 (0.0) 14 (14.0) 1 (4.5)
ORR, n (%) 58 (46.8) 4 (22.2) 2 (25.0) 50 (50.0) 8 (36.4)
 95% CI 37.8–55.9 6.4–47.6 3.2–65.1 39.8–60.2 17.2–59.3
DCR, n (%) 109 (87.9) 14 (77.8) 8 (100) 86 (86.0) 21 (95.5)
 95% CI 80.8–93.1 52.4–93.6 63.1–100.0 77.6–92.1 77.2–99.9
Median PFS (95% CI), months 9.9 (8.3–11.5) 5.2 (3.8–7.1) 7.6 (6.1–17.4) 9.9 (8.3–11.7) 9.9 (4.8–15.0)
 One-year PFS, n (%) 37.3 0.0 12.5 36.6 34.1
Median OS (95% CI), months 17.2 (13.5–21.4) 12.7 (9.3–21.0) 16.6 (10.6–26.7) 16.7 (12.4–20.1) 23.7 (15.2–31.5)
 One-year OS, n (%) 61.7 50 37.5 59.8 66.6
  1. CI: Confidence interval; CR: Complete response; DCR: Disease control rate; ORR: Overall response rate; OS: Overall survival; PR: Partial response; PD: Progressive disease; PFS: Progression-free survival; SD: Stable disease